The Phase I trial is an open label, dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of SPI-1620 in patients with recurrent or progressive carcinoma.
Rajesh Shrotriya, president and CEO of Spectrum Pharmaceuticals, said: “We believe that with further clinical development, SPI-1620 has the potential to significantly increase the efficacy of a broad range of chemotherapeutic drugs used for the treatment of solid tumors.”